Unleashing the Power of GFH009: A Promising CDK9 Inhibitor for Neuroendocrine Prostate Cancer Treatment – A Preclinical Study
Neuroendocrine Prostate Cancer: An Unmet Medical Need Solving the Puzzle with SELLAS Life Sciences Breaking Down the Latest News SELLAS Life Sciences Group, Inc. has recently announced groundbreaking results from a new preclinical study involving their highly selective CDK9 inhibitor, GFH009. This inhibitor has demonstrated significant potential in inhibiting cancer cell growth in preclinical models,…